Matthias Hebben

机构：Alexion Pharmaceuticals (United States), AstraZeneca (United States) · ORCID：0000-0002-2684-1153

发表论文 24 篇 · 总被引 748 次 · h-index 12

代表论文

• Production of lentiviral vectors (2016 · Molecular Therapy — Methods & Clinical Development · 被引 290)
• Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders (2022 · Science Advances · 被引 94)
• Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing (2015 · Molecular Therapy — Nucleic Acids · 被引 80)
• Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome (2018 · Molecular Therapy — Methods & Clinical Development · 被引 62)
• Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8 (2021 · Molecular Therapy — Methods & Clinical Development · 被引 45)
• Downstream bioprocessing of AAV vectors: industrial challenges & regulatory requirements (2018 · Cell and Gene Therapy Insights · 被引 39)